PAVmed announces 1-for-30 reverse stock split effective Jan 2, 2026 to regain Nasdaq compliance

PAVmed Inc.

1-for-30 reverse split effective Jan 2, 2026; authorized shares reduced from 250M to 25M.
Split intended to regain compliance with Nasdaq $1.00 minimum bid price requirement.
No fractional shares; all fractional shares rounded up to nearest whole share.
CUSIP changes to 70387R 502; ticker PAVM unchanged.
Stockholder approved at Dec 5 special meeting; board set ratio on Dec 8, 2025.

item 3.03 item 5.03 item 7.01 item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

PAVmed Inc. issued common stock.

Security: common stock

Exact text from the filing

it will conduct a 1-for-30 reverse stock split of its common stock (the “Common Stock”). The reverse stock split will become effective on January 2, 2026, at 12:01 a.m. Eastern Time.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PAVmed Inc.: Certificate of amendment to effect a 1-for-30 reverse stock split and reduce authorized common stock from 250,000,000 to 25,000,000 shares (effective 2026-01-02).

Change: charter amendment
Effective: 2026-01-02

Exact text from the filing

the Company filed a certificate of amendment to its certificate of incorporation, as amended, pursuant to which the Reverse Split and the Reduction in Authorized Common Stock will become effective on Friday, January 2, 2026, at 12:01 a.m. Eastern Time

View on SEC.gov

Browse all equity issuances →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-029510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.